It is worth noting that the frequency of p53 mutations in breast cancer is highly dependent on the subtype, with most hormone receptor-positive or luminal subtypes retaining a wild-type p53 status, whereas hormone receptor-negative patients predominantly carry p53 mutations with gain-of-function oncogenic activity, leading to a poorer prognosis. This evidence concerns the gene TP53 and breast cancer.